biotech · Blepharitis · Meibomian Gland Dysfunction · TARS
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals patent portfolio — 9 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 15440 Laguna Canyon Rd, Irvine, California 92618, US
- Founded
- 2017
- Employees
- 403
- Programs
- 14
- Drugs
- 10
- Patents
- 9
Tarsus Pharmaceuticals patents
9 pharmaceutical patents indexed for Tarsus Pharmaceuticals. 0 expire within 24 months.
Tarsus Pharmaceuticals has 9 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12364685
Isoxazoline parasiticide formulations
granted -
US 12257263
Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
granted -
US 12213964
Isoxazoline parasiticide formulations
granted -
US 12171750
Isoxazoline parasiticide formulations and methods for treating blepharitis
granted -
US 11752137
Ophthalmic compositions for treating ocular Demodex using lotilaner formulations
granted -
US 11690826
Methods for treating demodex blepharitis using lotilaner formulations
granted -
US 11690827
Methods for treating ocular Demodex using lotilaner formulations
granted -
US 11197847
Isoxazoline parasiticide formulations and methods for treating blepharitis
granted -
US 10835517
Methods for treating ocular demodex using isoxazoline parasiticide formulations
granted
Frequently asked questions
How many patents does Tarsus Pharmaceuticals have?
9 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Tarsus Pharmaceuticals patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.